Innovative Molecular Platform for Prenatal Diagnostics

Information

  • Research Project
  • 8120144
  • ApplicationId
    8120144
  • Core Project Number
    R43HD069052
  • Full Project Number
    1R43HD069052-01
  • Serial Number
    69052
  • FOA Number
    PA-10-050
  • Sub Project Id
  • Project Start Date
    3/5/2011 - 14 years ago
  • Project End Date
    8/31/2011 - 14 years ago
  • Program Officer Name
    URV, TIINA K
  • Budget Start Date
    3/5/2011 - 14 years ago
  • Budget End Date
    8/31/2011 - 14 years ago
  • Fiscal Year
    2011
  • Support Year
    1
  • Suffix
  • Award Notice Date
    3/3/2011 - 14 years ago
Organizations

Innovative Molecular Platform for Prenatal Diagnostics

DESCRIPTION (provided by applicant): The goal of this application is to develop a customized molecular platform for prenatal diagnosis that combines our proprietary padlock probe technology with the power of next-generation sequencing. The molecular platform combines comprehensiveness with customization more effectively than currently available methods, and promises to reduce per sample cost of goods to below $100. The technology enables simultaneous detection of Mendelian disorders, aneuploidy, uniparental disomy, and unbalanced structural abnormalities. Sequence capture is performed multiplexed in a single tube, in conjunction with any next-generation sequencing platform. Because the method is easy to customize, molecular geneticists will be able to add new alleles or create customized pools for certain at-risk ethnic populations. Once they are synthesized, individual probe freezer stocks can be mixed to create customized pools for virtually any future application. This application proposes to optimize the padlock probe technology and then build a 200,000-plex probe pool for prenatal diagnostics. First, we propose to map the genome coordinates for disease alleles from 18 Mendelian congenital disorders of interest to the prenatal specialist. Second, we propose to build a 1,000-plex pilot probe pool that will be used to optimize probe design, synthesis, and sequence capture. Third, we propose to use these optimized to synthesize a 200,000-plex probe pool specifically for prenatal diagnostics. Finally, we will validate the molecular technology on archival genomic DNA, amniotic fluid, and fetal nucleated red blood cells (FNRBCs). Eventually, we will market the technology to laboratories performing routine amniotic screening as well as noninvasive prenatal diagnostics. The probe pool could also be used generically for any routine molecular karyotyping application, such as cancer diagnostics or preimplantation genetic diagnosis. PUBLIC HEALTH RELEVANCE: We are developing new methods that will help to detect genetic problems before babies are born. Current methods are expensive and not customizable. We are using new technology for DNA sequencing that may one day make this process easier for geneticists.

IC Name
EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT
  • Activity
    R43
  • Administering IC
    HD
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    201616
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    865
  • Ed Inst. Type
  • Funding ICs
    NICHD:201616\
  • Funding Mechanism
    SBIR-STTR
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    GIGAGEN, INC.
  • Organization Department
  • Organization DUNS
    963285189
  • Organization City
    SAN FRANCISCO
  • Organization State
    CA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    941582509
  • Organization District
    UNITED STATES